Quantcast
Last updated on April 21, 2014 at 1:20 EDT

Latest Pregabalin Stories

2014-03-28 12:26:21

DUBLIN, March 28, 2014 /PRNewswire/ -- Dublin - Research and Markets ( http://www.researchandmarkets.com/research/qx6h7s/investigation) has announced the addition of the "Investigation Report on China Pregabalin Market, 2009-2018" [http://www.researchandmarkets.com/research/qx6h7s/investigation ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) Neuropathic pain is caused by damage or pathological changes of nervous system. Its...

2014-03-11 23:33:37

ChinaMarketResearchReports.com adds Latest Reports on China Sildenafil and Pregabalin Market to its store. Dallas, TX (PRWEB) March 11, 2014 There are hundreds of millions of males suffering from sexual dysfunction in the world, of which over 50 million are in China. Statistics indicates that more than 60% of males aged above 35 in China have sexual dysfunction of different degrees. About 50% of the causes of erectile dysfunction are organic, and 30% are psychological while 20% of them...

2014-02-06 12:27:58

Several Emerging Therapies are Poised to Provide Improvements in Safety and Tolerability and/or Delivery, According to Findings from Decision Resources Group BURLINGTON, Mass., Feb. 6, 2014 /PRNewswire/ -- Decision Resources Group finds that greater reduction in pain intensity and a greater patient responder rate (measured by the percentage of patients reporting at least 30 percent or at least 50 percent reduction in pain intensity from baseline) are the top two areas of unmet need in painful...

2014-01-14 08:29:24

SAN FRANCISCO, Jan. 14, 2014 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that the first subjects were dosed in a Phase 1 clinical study for NKTR-171, a new sodium channel blocker being developed as an oral therapy for the treatment of peripheral neuropathic pain. The single-ascending dose Phase 1 clinical study of NKTR-171 will assess its pharmacokinetics, tolerability, and safety in up to 50 healthy subjects. NKTR-171 is a new molecular entity that is...

2013-05-28 12:26:28

Improved Safety and Tolerability Compared with Current Therapies is Another Key Market Access Lever for Emerging Neuropathic Pain Therapies, According to a New Report from Decision Resources BURLINGTON, Mass., May 28, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that expanded labeling for additional neuropathic pain (NP) populations and/or broader NP labeling (peripheral NP) will not...

2013-05-22 23:16:58

Printable Discount Cards from MedicationDiscountCard.com for Lyrica Margate City, NJ (PRWEB) May 22, 2013 The health care crisis in the United States is far from solved. In some states, up to twenty-seven percent of all adults are without health insurance. Further, roughly half of all bankruptcies of private citizens in the U.S. are related to medical bills. The high price of medical care also affects prescription drugs, meaning that many patients cannot afford to take their...

2013-04-09 12:27:26

Greater Reduction in Pain Intensity is One of the Greatest Unmet Needs in Postherpetic Neuralgia, According to a New Report from Decision Resources BURLINGTON, Mass., April 9, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed U.S. and European neurologists agree that reduction in pain intensity is one of the attributes that most influences their decisions regarding prescribing...

2012-12-05 05:01:17

Dr. J Marshall Dent has learned from fibromyalgia patients that three things have a dramatic impact on their improvement: reduce oxidative stress, reduce sugar in the diet, and the use of human chorionic gonadotropin or hCG. Columbia, SC (PRWEB) December 04, 2012 There are many times in medicine when doctors learn more from their patients than they could ever learn from a textbook. One such example is in the treatment of fibromyalgia. Fibromyalgia is characterized by chronic pain and...

2012-09-05 06:25:07

AACHEN, Germany, September 5, 2012 /PRNewswire/ -- Targeted Treatment for Patients Suffering from Postherpetic Neuralgia: It's a Control Thing - This press Information is meant exclusively for trade press. - We do not approve publication in lay press. Ask pain patients what they expect from their treatment and the answer is simple: "I want to sleep through the whole night," or, "I want to be able to walk with my wife." They want relief with minimal side...

2012-07-05 06:23:09

MUMBAI and BALTIMORE, July 5, 2012 /PRNewswire/ -- Pharma major, Lupin Ltd., announced today that its subsidiary, Lupin Pharmaceuticals Inc. (collectively, Lupin) has received final approval for its Pregabalin Capsules, 25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg and 300 mg from the United States Food and Drugs Administration (FDA) to market a generic version of C.P. Pharmaceuticals C.V., LYRICA(R) (Pregabalin) capsules. Lupin's Pregabalin Capsules, 25 mg, 50 mg,...


Latest Pregabalin Reference Libraries

Generalized Anxiety Disorder
2013-07-25 15:07:54

Generalized Anxiety Disorder (GAD) is an anxiety disorder with worry about normal, everyday situations such as finance, health and wellbeing in relationships (personal and work related) all lasting longer than six months. Symptoms The symptoms of GAD can include but are not limited to difficulty swallowing, rashes, shortness of breath, fidgeting, headaches, tension, nausea, etc. In order for GAD to be ruled as present, the symptoms and feelings must be experiences for at least six...

More Articles (1 articles) »